LONDON, Dec. 4, 2014 /PRNewswire/ -- Lightlake
Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical
company developing addiction treatments based on its expertise in
opioid antagonists, announced today that Lightlake has begun a
trial designed to evaluate its intranasal naloxone application for
opioid overdose.
The trial is being conducted in partnership with the National
Institute on Drug Abuse ("NIDA"), a part of the National Institutes
of Health ("NIH"), a part of the U.S. Department of Health and
Human Services.
Naloxone, a medicine currently available via injection, can
rapidly reverse the overdose of prescription and illicit opioids.
Lightlake is developing a new intranasal delivery system for the
delivery of naloxone that could widely expand its availability and
use in preventing opioid overdose deaths, a public health problem
of epidemic proportion in the U.S. According to the Centers for
Disease Control and Prevention (CDC), 16,651 people died from
prescription opioid overdose in the U.S. in 2010, a dramatic
increase from the 4,030 overdose deaths in 1999.
Assuming favorable outcomes from this study, a New Drug
Application ("NDA") with the U.S. Food and Drug Administration
("FDA") is expected to be filed. The ultimate goals of Lightlake's
partnership with NIDA are to submit an NDA and receive approval
from the FDA for Lightlake's intranasal naloxone solution for the
reversal of opioid overdoses, and bring it to market.
"This trial will build on the previous successful trial
conducted in collaboration with NIDA last year. We have now
optimized our formulation and device, and look forward to the
clinical results that will bring us closer to launching a
critically needed commercial product that can save lives," stated
Dr. Roger Crystal, CEO of
Lightlake.
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc., a biopharmaceutical company, is
using its expertise in opioid antagonists to build a platform of
innovative intranasal naloxone solutions to common addictions and
related disorders. Lightlake is developing a treatment to reverse
opioid overdoses, which have reached epidemic proportions in
the United States. Lightlake has
completed a clinical trial for this treatment in collaboration with
the National Institute on Drug Abuse ("NIDA"), part of the National
Institutes of Health, and has commenced a second study in
collaboration with NIDA. Lightlake also has completed a Phase II
clinical trial to treat Binge Eating Disorder. For more information
please visit: http://www.lightlaketherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," "estimates," "predicts," "projects,"
"potential," or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
press release to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
Corporate Contact:
Lightlake Therapeutics Inc.
Dr. Roger Crystal, CEO
+44(0)203 617 8739
info@lightlaketherapeutics.com
Investor Relations Contact:
Amato and Partners, LLC
admin@amatoandpartners.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lightlake-therapeutics-commences-trial-for-treatment-of-opioid-overdose-with-the-us-national-institute-on-drug-abuse-nida-300004602.html
SOURCE Lightlake Therapeutics Inc.